机构:Univ Utah, Hlth Sci Ctr, Div Hematol, Dept Pharm Serv, Salt Lake City, UT 84132 USA
Silverstein, SB
Rodgers, GM
论文数: 0引用数: 0
h-index: 0
机构:
Univ Utah, Hlth Sci Ctr, Div Hematol, Dept Pharm Serv, Salt Lake City, UT 84132 USAUniv Utah, Hlth Sci Ctr, Div Hematol, Dept Pharm Serv, Salt Lake City, UT 84132 USA
Rodgers, GM
[1
]
机构:
[1] Univ Utah, Hlth Sci Ctr, Div Hematol, Dept Pharm Serv, Salt Lake City, UT 84132 USA
[2] Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA
[3] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA
Parenteral iron therapy is occasionally necessary for patients intolerant or unresponsive to oral iron therapy, for receiving recombinant erythropoietin therapy, or for use in treating functional iron deficiency. There are now three parenteral iron products available: iron dextran, ferric gluconate, and iron sucrose. We summarize the advantages and disadvantages of each product, including risk of anaphylaxis and hypersensitivity, dosage regimens, and costs. The increased availability of multiple parenteral iron preparations should decrease the need to use red cell transfusions in patients with iron-deficiency anemia. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:74 / 78
页数:5
相关论文
共 20 条
[1]
[Anonymous], 1997, Am J Kidney Dis, V30, pS192